Resolution Pharmaceuticals inks deals

June 5, 1996

Radiopharmaceutical developer Resolution Pharmaceuti-cals of Mississauga,Ontario, has entered into two R&D collaborations with Canadianinstitutes to develop new imaging agents. Both deals have thesupport of Canadian research agencies. In the first

Radiopharmaceutical developer Resolution Pharmaceuti-cals of Mississauga,Ontario, has entered into two R&D collaborations with Canadianinstitutes to develop new imaging agents. Both deals have thesupport of Canadian research agencies.

In the first deal, Resolution and the Alberta Peptide Institutewill receive up to $200,000 from the National Research Council'sIndustrial Research Assistance Program to investigate new radiopharmaceuticalsto image bacterial and fungal infections.

In the second deal, Resolution and the Ontario Cancer Centerreceived a $50,000 grant from the Medical Research Council ofCanada to research compounds to be used in functional medicalimaging that could also be used to aid disease treatment suchas chemotherapy.

Resolution Pharmaceuticals is a joint venture between Canadianradioisotope producer Nordion International and Allelix Biopharmaceuticals.The company's peptide-based radiopharmaceutical for imaging inflammatorydisease completed phase I clinical testing earlier this year (SCAN1/17/96).